Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Annette Kubalek

Nurse Practitioner Indiana, PA Nurse Practitioner

NPI 1376089334 CMS profile 10483644

1265 Wayne Ave Ste 103, Indiana, PA 15701

Open in the dashboard

General payments

$56,365

416 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Annette Kubalek of Indiana, PA is reported in the CMS Open Payments database as having received $56,365 across 416 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43,799 267
2024 General $6,861 48
2023 General $4,358 36
2022 General $626 29
2021 General $721 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Annette Kubalek
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Annette Kubalek were reported at $43,799. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Annette Kubalek Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $721 $135 $40–$426 $132
2022 $626 $152 $48–$470 $149
2023 $4,358 $166 $54–$529 $160
2024 $6,861 $173 $55–$556 $164
2025 $43,799 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $49,092 238 payments
  2. Ascensia Diabetes Care US Inc. $3,032 8 payments
  3. Bigfoot Biomedical Inc $825 8 payments
  4. Tandem Diabetes Care, Inc. $551 27 payments
  5. Lilly USA, LLC $326 18 payments
  6. Medtronic, Inc. $307 14 payments
  7. Averitas Pharma Inc. $233 13 payments
  8. Mannkind Corporation $225 7 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $182 9 payments
  10. Amgen Inc. $165 7 payments
  11. Other $1,429 67 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $26,914 363 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $17,563 24 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,075 3 payments
  4. Travel and Lodging $3,923 21 payments
  5. Consulting Fee $3,890 5 payments
Products named General payments · program years 2021–2025
  1. FreeStyle Libre 3 $49,066 236 payments
  2. UNITY DIABETES MANAGEMENT SYSTEM $825 8 payments
  3. t:slim X2 Insulin Pump with Control-IQ $376 23 payments
  4. Qutenza $300 17 payments
  5. MOUNJARO $229 12 payments
  6. MINIMED 780G $226 9 payments
  7. AFREZZA $225 7 payments
  8. Kerendia $182 9 payments
  9. t-slim insulin pump $175 4 payments
  10. TEPEZZA $161 2 payments
  11. Other $1,811 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 100 drugs

Part D claims

8,929

Median for Nurse Practitioner: 389

Drug cost

$4,099,187

Median for Nurse Practitioner: $21,885

Branded share of claims

67.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 780 $876,781
Trulicity Dulaglutide Brand 425 $464,059
Xultophy 100-3.6 Insulin Degludec/Liraglutide Brand 251 $370,565
Jardiance Empagliflozin Brand 367 $307,948
Mounjaro Tirzepatide Brand 240 $247,544
Farxiga Dapagliflozin Propanediol Brand 218 $165,219
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 165 $134,414
Synjardy Xr Empagliflozin/Metformin Hcl Brand 175 $131,817
Invokana Canagliflozin Brand 122 $119,834
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 191 $116,839

The 10 drugs with the highest cost, of 100 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$40,082

Medicare's payments for the services billed

Medicare patients

242

Average age 72

Services billed

3,819

145 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 67%
Arthritis 47%
Chronic kidney disease 31%
Ischemic heart disease 27%
Depression 24%
Osteoporosis 19%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEPEZZA
$50 — —
Qutenza
$47 — —
Kerendia
$36 41 —
MOUNJARO
$30 240 —
JARDIANCE
$30 367 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

416 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record